Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;41(9):809-816.
doi: 10.1007/s40261-021-01064-z. Epub 2021 Aug 10.

The Impact of Non-dopaminergic Medication on Quality of Life in Parkinson's Disease

Nicol G M Oonk  1 , Kris L L Movig  2 , Job van der Palen  3   4 , Henk-Willem Nijmeijer  5 , Mirjam E van Kesteren  6 , Lucille D A Dorresteijn  7
Affiliations

The Impact of Non-dopaminergic Medication on Quality of Life in Parkinson's Disease

Nicol G M Oonk et al. Clin Drug Investig. 2021 Sep.

Abstract

Background and objectives: Quality of life (QoL) in Parkinson's disease (PD) depends on multiple factors. Due to PD treatment and accompanying, age-related or independent comorbidities, pill burden is often high. The relation of QoL and pharmacotherapy for comorbidities in PD has not been widely studied. This study investigated if and to what extent non-dopaminergic drugs are related to QoL in PD. Second, the impact of demographics and non-motor symptoms were evaluated. A better understanding of the impact of different non-dopaminergic drugs and polypharmacy on QoL will have added value in selecting appropriate (medication) interventions.

Methods: In a cross-sectional analysis, medication prescription data of 209 PD patients were analyzed and grouped according to the Rx-Risk comorbidity index. QoL was measured using the PDQ-39 questionnaire. Non-motor symptoms were analyzed with the Non-Motor Symptoms questionnaire. Independent factors associated with a reduced QoL were identified with a multivariate linear regression analysis.

Results: Non-dopaminergic drugs, subdivided into Rx-Risk comorbidity categories, were not associated with reduced QoL, except for the use of anti-epileptic drugs. However, using more daily non-dopaminergic drugs was also negatively associated with QoL, as well as female sex, increased PD severity, and more non-motor symptoms. Contraindicated non-dopaminergic medication was barely prescribed (0.4%).

Conclusion: Non-dopaminergic drugs are frequently prescribed, and higher numbers are associated with impaired QoL in PD. However, when divided in drug types, only anti-epileptic drugs were negatively associated with QoL. In these patients, physicians might improve QoL by further optimizing the condition it was prescribed for (e.g., pain or anxiety), or managing of side effects.

Trial registration: Netherlands Trial Register; NL4360.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Dorsey E, Constantinescu R, Thompson J, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–6. https://doi.org/10.1212/01.wnl.0000271777.50910.73 . - DOI - PubMed
    1. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912. https://doi.org/10.1016/S0140-6736(14)61393-3 . - DOI - PubMed
    1. Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord. 2010;25(15):2493–500. https://doi.org/10.1002/mds.23394 . - DOI - PubMed
    1. Muslimovic D, Post B, Speelman JD, et al. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology. 2008;70(23):2241–7. https://doi.org/10.1212/01.wnl.0000313835.33830.80 . - DOI - PubMed
    1. McLean G, Hindle J, Guthrie B, Mercer S. Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database. BMC Neurol. 2017;17(1):126. https://doi.org/10.1186/s12883-017-0904-4 . - DOI - PubMed - PMC

LinkOut - more resources